Descrizione

A study by StrategyHelix indicates that the global biological therapies for cancer market is expected to increase by US$ 50.0 miliardi da 2022 A 2028, ottenendo un CAGR di 8.2% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for biological therapies for cancer. The global biological therapies for cancer market is segmented on the basis of product, e regione. In base al prodotto, the global biological therapies for cancer market is categorized into CAR T-cell therapies, monoclonal antibodies, vaccines. The monoclonal antibodies segment held the largest share of the global biological therapies for cancer market in 2021 e si prevede che manterrà la sua quota durante il periodo di previsione. In termini di geografia, the global biological therapies for cancer market has been segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW). Globally, North America made up the largest share of the biological therapies for cancer market.

The global biological therapies for cancer market is highly competitive. Some of the leading companies operating in the market are Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the biological therapies for cancer market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Prodotto: CAR T-cell therapies, monoclonal antibodies, vaccines
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global biological therapies for cancer market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Biological therapies for cancer market overview
Parte 3. Ripartizione del mercato per prodotto
– CAR T-cell therapies
– Monoclonal antibodies
– Vaccines
Parte 4. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 5. Aziende chiave
– Amgen Inc.
– AstraZeneca plc
– Bristol-Myers Squibb Company (BMS)
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Genmab A/S
– Gilead Sciences, Inc.
– GlaxoSmithKline plc (GSK)
– Janssen Pharmaceuticals, Inc.
– Merck KGaA
– Novartis International AG
– Pfizer Inc.
Informazioni su StrategyHelix
Disclaimer